Cap: $262.5M
Runway: Mid-2027
Clinical Pipeline (Compendium View)
| Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|
| Cemsidomide (CFT7455) | Multiple Myeloma | Phase 2 (MOMENTUM) | First Patient Dosed: March 2026 |
| CFT1946 | BRAF V600 Mutant Cancers | Phase 1/2 | Dose Expansion Data: Q2 2026 |
Latest SEC Filings
Active Clinical Trials
Operational Overview
Operational Overview
C4 is a leader in the “Molecular Glue” space. Their operational efficiency has improved significantly in 2026, beating EPS estimates in February and maintaining a strong $290M+ cash position.
Strategic Value
The partnership with Merck KGaA and the recent dosing in the MOMENTUM trial validate the platform. The “Degrader” modality is increasingly being eyed by Big Pharma for M&A as a cleaner alternative to traditional inhibitors.